Leap Therapeutics Stock Total Asset
| LPTX Stock | USD 2.91 0.02 0.69% |
Leap Therapeutics fundamentals help investors to digest information that contributes to Leap Therapeutics' financial success or failures. It also enables traders to predict the movement of Leap Stock. The fundamental analysis module provides a way to measure Leap Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Leap Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 72.8 M | 45.2 M | |
| Intangibles To Total Assets | 0.01 | 0.01 |
Leap | Total Asset |
Leap Therapeutics Company Total Asset Analysis
Leap Therapeutics' Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Leap Therapeutics Total Asset | 72.83 M |
Most of Leap Therapeutics' fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Leap Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Leap Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Leap Therapeutics is extremely important. It helps to project a fair market value of Leap Stock properly, considering its historical fundamentals such as Total Asset. Since Leap Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Leap Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Leap Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Leap Total Asset Historical Pattern
Today, most investors in Leap Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Leap Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Leap Therapeutics total asset as a starting point in their analysis.
Leap Therapeutics Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Leap Total Assets
Total Assets |
|
Based on the latest financial disclosure, Leap Therapeutics has a Total Asset of 72.83 M. This is 99.03% lower than that of the Biotechnology sector and 96.31% lower than that of the Health Care industry. The total asset for all United States stocks is 99.75% higher than that of the company.
Leap Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Leap Therapeutics' direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Leap Therapeutics could also be used in its relative valuation, which is a method of valuing Leap Therapeutics by comparing valuation metrics of similar companies.Leap Therapeutics is currently under evaluation in total asset category among its peers.
Leap Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Leap Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Leap Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Leap Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Leap Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Leap Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Leap Therapeutics' value.| Shares | Blackrock Inc | 2024-06-30 | 172.1 K | Ubs O'connor Llc | 2024-09-30 | 165.1 K | Longwood Capital Partners Llc | 2024-09-30 | 120.5 K | Exome Asset Management Llc | 2024-09-30 | 102.6 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 81.5 K | State Street Corp | 2024-09-30 | 71.8 K | Susquehanna International Group, Llp | 2024-09-30 | 66.2 K | Northern Trust Corp | 2024-09-30 | 61.6 K | Marshall Wace Asset Management Ltd | 2024-09-30 | 52.9 K | Balyasny Asset Management Llc | 2024-09-30 | 3.1 M | Samsara Biocapital, Llc | 2024-09-30 | 2.4 M |
Leap Fundamentals
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 48.29 M | ||||
| Shares Outstanding | 38.32 M | ||||
| Shares Owned By Insiders | 17.28 % | ||||
| Shares Owned By Institutions | 40.30 % | ||||
| Number Of Shares Shorted | 1.42 M | ||||
| Price To Earning | (1.85) X | ||||
| Price To Book | 2.26 X | ||||
| Price To Sales | 160.10 X | ||||
| Gross Profit | 1.5 M | ||||
| EBITDA | (80.99 M) | ||||
| Net Income | (81.41 M) | ||||
| Cash And Equivalents | 90.88 M | ||||
| Cash Per Share | 0.92 X | ||||
| Total Debt | 262 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.88 X | ||||
| Book Value Per Share | 2.35 X | ||||
| Cash Flow From Operations | (43.75 M) | ||||
| Short Ratio | 2.68 X | ||||
| Earnings Per Share | (1.64) X | ||||
| Price To Earnings To Growth | 0.75 X | ||||
| Target Price | 9.83 | ||||
| Number Of Employees | 54 | ||||
| Beta | 0.22 | ||||
| Market Capitalization | 110.74 M | ||||
| Total Asset | 72.83 M | ||||
| Retained Earnings | (399.58 M) | ||||
| Working Capital | 58.91 M | ||||
| Current Asset | 2.38 M | ||||
| Current Liabilities | 22.01 M | ||||
| Net Asset | 72.83 M |
About Leap Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Leap Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Leap Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Leap Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.